Discover how the emerging biomarker EMP3 is revolutionizing the prognosis of glioblastoma by linking to the pivotal process of epithelial-mesenchymal transition (EMT).
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
EMP3 as a prognostic biomarker correlates with EMT in GBM.
Li et al., BMC Cancer 2024
DOI: 10.1186/s12885-023-11796-0
What’s New: The study identifies Epithelial membrane protein 3 (EMP3) as a key player in the progression of glioblastoma (GBM), particularly in its role in epithelial-mesenchymal transition (EMT), which is crucial for the malignancy of GBM. EMP3 is highlighted as a potential biomarker for diagnosis and an independent prognostic factor for overall survival in glioma patients.
Importance: This research provides insights into the mechanisms of GBM malignancy and suggests that targeting EMP3 could be a therapeutic strategy. It also offers a new biomarker for the diagnosis and prognosis of glioma, which could improve patient management.
Contribution to Literature: The study uses bioinformatics analysis of large databases (CGGA and TCGA), single-cell RNA sequencing datasets, and experimental validation through cell line assays to demonstrate the role of EMP3 in GBM. It shows that EMP3 is enriched in high-grade and IDH wild-type gliomas, and that silencing EMP3 reduces GBM cell proliferation and migration. EMP3’s promotion of EMT is suggested as the mechanism behind its effect on tumor malignancy.